<unk>  (INN) is a semisynthetic aminoglycoside antibiotic. It is primarily used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA).<unk>  was originally synthesized from dibekacin in 1973. It has been registered and marketed in Japan since 1990 under the trade name Habekacin.<unk>  is no longer covered by patent and generic versions of the drug are also available under such trade names as Decontasin and Blubatosine.
Arbekacin
Darifenacin
Solifenacin
Simvastatin
Probenecid
Fluvastatin
Revefenacin
Proglumetacin